Trastuzumab: A picky partner?

Heather L. McArthur, Clifford A. Hudis

Research output: Contribution to journalComment/debatepeer-review

3 Scopus citations


Preclinical and clinical models of HER2-positive breast cancer show that human epidermal growth factor receptor 2 (HER2)-targeted therapy with trastuzumab adds significant benefits and modest risks to conventional cytotoxic therapies. Building on this advance will likely depend on elucidation of relevant signaling pathways and mechanisms of action for effective HER2-targeted therapies.

Original languageEnglish (US)
Pages (from-to)6311-6313
Number of pages3
JournalClinical Cancer Research
Issue number20
StatePublished - Oct 15 2009
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Trastuzumab: A picky partner?'. Together they form a unique fingerprint.

Cite this